Drospirenone 4 mg-only pill (DOP) in 24+4 regimen: a new option for oral contraception

References

• Graham S, Fraser IS. The progestogen only mini-pill. Contraception. 1982;26(4):373–388.
   PubMed Web of Science ®Google Scholar
• Grandi G, Cagnacci A, Volpe A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2014;10(1):1–10.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Contraception. 1998;57(5):315.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. Geneva: WHO; 2015.
   Google Scholar
• Centers for Disease Control and Prevention (CDC). US Medical Eligibility Criteria for Contraceptive Use. Recommendations and Reports. 65(3); July292016.
   Web of Science ®Google Scholar
• Faculty of Sexual and Reproductive Healthcare. UK medical eligibility criteria for contraceptive use (UKMEC). London: FSRH; 2016.
   Google Scholar
• Kovacs G. Progestogen-only pills and bleeding disturbances. Hum Reprod. 1996;11(2):20–23.
   PubMedGoogle Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62(1):29–38.
   PubMed Web of Science ®Google Scholar
• Grandi G, Mueller MD, Bersinger NA, et al. The association between progestins, nuclear receptors expression and inflammation in endometrial stromal cells from women with endometriosis. Gynecol Endocrinol. 2017;33(9):712–715.
   PubMed Web of Science ®Google Scholar
• Muhn P, Fuhrmann U, Fritzemeier H, et al. Drospirenone: a novel progestogen with antimineralcorticoid and antiandrogenic activity. Ann N Y Acad Sci. 1995;761(1):311–335.
   PubMedGoogle Scholar
• Elger W, Beier S, Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003;68(10–13):891–905.
   PubMed Web of Science ®Google Scholar
• Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing animineralcorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80(6):1816–1821.
   PubMed Web of Science ®Google Scholar
• Nickisch K, Beier S, Bittler D, et al. Aldosterone antagonists. 4. Synthesis and activities of steroidal 6,6-ethylene-15,16-methylene 17-spironolactones. J Med Chem. 1991;34(8):2464–2468.
   PubMed Web of Science ®Google Scholar
• Nickisch K, Bittler D, Casals-Stenzel J, et al. Aldosterone antagonist. 1. Synthesis and activities of 6 beta, 7 beta:15 beta,16 beta-dimethylene steroidal spironolactones. J Med Chem. 1985;28(5):546–550.
   PubMed Web of Science ®Google Scholar
• Laurent H, Bittler D, Hofmeister H, et al. Synthesis and activities of anti-aldosterone. J Steroid Biochem 1983; 19(1C):771-776]LosertW, Casals-Stenzel J, Buse M. Progestogens with antiminerlcorticoid activity. Arzneimittelforschung. 1985;35(2):459–471.
   PubMedGoogle Scholar
• Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climateric. 2005;8(3):4–12.
   PubMedGoogle Scholar
• Grandi G, Del Savio MC, Lopes da Silva Filho A, et al. Estetrol (E4): the new estrogenic component of combined oral contraceptives. Expert Rev Clin Pharmacol. 2020;7:1–4.
   Google Scholar
• Oelkers WK. Effects of estrogen and progestogens on the aldosterone system and blood pressure. Steroids. 1996;61(4):166–171.
   PubMed Web of Science ®Google Scholar
• Krause W, Kuhne G. Isolation and identification of spirenone metabolites from the monkey (Macaca fascicularis). Steroids. 1982;40(1):81–90.
   PubMed Web of Science ®Google Scholar
• Stanczyk F. Pharmacokinetics and potency of progestins used for hormone replacement therapy and contraception. Rev Endocrin Metab Disord. 2002;3(3):211–224.
   PubMedGoogle Scholar
• Richter WH, Koytchev R, Kirkov V, et al. Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females. Contraception. 2020;101(2):137-143.
   PubMed Web of Science ®Google Scholar
• Wiesinger H, Berse M, Klein S, et al. Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol. Br J Clin Pharmacol. 2015;80(6):1399–1410.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause. 2002;9(1):6–15.
   PubMed Web of Science ®Google Scholar
• Fuhrmann U, Krattenmacher R, Slater EP, et al., The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996; 54(4):243–251.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004;47(4):277–283.
   PubMed Web of Science ®Google Scholar
• Muhn P, Krattenmacher R, Beier S, et al. Drospirenone: a novel progestogen with antimineralcorticoid and antiandrogenic activity: pharmacological characterization in animal models. Contraception. 1995;51(2):999.
   Google Scholar
• Rosenbaum P, Schmidt W, Helmerhorts M, et al. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestrdiol. Eur J Contraception Reprod Health Care. 2000;5(1):16–24.
   PubMedGoogle Scholar
• Theichmann A. Pharmacology of estradiol valerate/dienogest. Climateric. 2003;6(2):17–23.
   PubMedGoogle Scholar
• Oelkers W, Berger V, Bolik A, et al. Dihydrospirenone, a new progestogen with antimineralcorticoid activity: effects on ovulation, electrolyte excretion, and renin-aldosterone system in normal women. J Clin Endocrin Metab. 1991;73(4):837–842.
   PubMed Web of Science ®Google Scholar
• Duijkers IJ, Heger-Mahn D, Drouin D, et al., A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24/4 regimen. Eur J Contracept Reprod Health Care. 2015;20(6): 419–427.
   PubMed Web of Science ®Google Scholar
• Duijkers IJM, Heger-Mahn D, Drouin D, et al. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016;93(4):303–309.
   PubMed Web of Science ®Google Scholar
• Archer DF, Ahrendt HJ, Drouin D. Drospirenone-only oral contraceptive: results from a multicenter noncomparative trial of efficacy, safety and tolerability. Contraception. 2015;92(5):439–444.
   PubMed Web of Science ®Google Scholar
• Palacios S, Colli E, Regidor PA. Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill. Acta Obstet Gynecol Scand. 2019;98(12):1549–1557.
   PubMed Web of Science ®Google Scholar
• Kimble T, Burke AE, Barnhart KT, et al. A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen. Contraception. 2020;2:100020.
   Google Scholar
• Schindler AE. Differential effects of progestins on the hemostasis. Maturitas. 2003;46:31–37.
   PubMed Web of Science ®Google Scholar
• Grandi G, Napolitano A, Cagnacci A. Metabolic impact of combined hormonal contraceptives containing estradiol. Expert Opin Drug Metab Toxicol. 2016;12(7):779–787.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Colli E, Schindler AE. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 μg per day. Gynecol Endocrinol. 2016;32(9):749–751.
   PubMed Web of Science ®Google Scholar
• Palacios S, Colli E, Regidor PA. A multicenter, double-blind, randomized trial on the bleeding profile of a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg. Arch Gynecol Obstet. 2019;300(6):1805–1812.
   PubMed Web of Science ®Google Scholar
• Apter D, Colli E, Gemzell Danielsson K, et al. Multicenter, Open-Label Trial to Assess the Safety and Tolerability of Drospirenone 4.0 mg Over 6 Cycles in Female Adolescents, With a 7-Cycle Extension Phase. Contraception. 2020;101(6):412-419.
   PubMed Web of Science ®Google Scholar
• Regidor PA, Colli E, Georgiev D, et al. Safety, influence on the endometrium, sonographic changes and bleeding profile after 13 cycles with the new drospirenone only pill (DOP) for contraception. Horm Mol Biol Clin Investig. 2020. DOI:10.1515/hmbci-2019-0061
   PubMedGoogle Scholar
• Ludicke F, Johannisson E, Helmerhorst FM, et al. Effect of a combination oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium. Fertil Steril. 2001;76(1):102–107.
   PubMed Web of Science ®Google Scholar
• McCann MF, Potter LS. Progestin-only oral contraception: A comprehensive review. Contraception. 1994;50(1):S9–195.
   Google Scholar
• Rice CF, Killick SR, Dieben T, et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 μg daily. Hum Reprod. 1999;14:982–985.
   PubMed Web of Science ®Google Scholar
• Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation with the 75-μg desogestrel-only contraceptive pill (cerazette) after scheduled 12-h delays in tablet intake. Contraception. 2005;71(1):8–13.
   PubMed Web of Science ®Google Scholar
• Palacios S, Wildt L, Parke S, et al. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):57–62.
   PubMed Web of Science ®Google Scholar
• Gerlinger C, Trussell J, Mellinger U, et al. Different Pearl Indices in studies of hormonal contraceptives in the United States: impact of study population. Contraception. 2014;90(2):142–146.
   PubMed Web of Science ®Google Scholar
• Orleans RJ Center for Drug Evaluation and Research, Application number 22–262, LoSeasonique™. 2008 Oct 23.
   Google Scholar
• Center for Drug Evaluation and Research, Application number 022501Orig1s000. Lo Loestrin Fe. 2010 Oct 4.
   Google Scholar
• Quartette: an ascending-dose, extended-cycle oral contraceptive. Med Lett Drugs Ther. 2013 Jul 8;55(1420):54–55.
   PubMed Web of Science ®Google Scholar
• Nelson A, Parke S, Makalova D, et al. Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: a pooled analysis of three studies conducted in North America and Europe. Eur J Contracept Reprod Health Care. 2013;18(4):264–273.
   PubMed Web of Science ®Google Scholar
• Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61(2):105–111.
   PubMed Web of Science ®Google Scholar
• Bachmann G, Sulak PJ, Sampson-Landers C, et al. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70(3):191–198.
   PubMed Web of Science ®Google Scholar
• Apter D, Zimmerman Y, Beekman L, et al. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA). Contraception. 2016;94(4):366–373.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kaunitz AM, Bitzer J. Extended regimen combined oral contraception: A review of evolving concepts and acceptance by women and clinicians. Eur J Contracept Reprod Health Care. 2016;21(2):106–115.
   PubMed Web of Science ®Google Scholar
• Affinito P, Monterubbianesi M, Primizia M, et al. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol. Gynecol Endocrinol. 1993;7(4):259–266.
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Dietrich H, Wisser KH, et al. The efficacy and tolerability of Valette: a postmarketing surveillance study. Eur J Contracept Reprod Health Care. 1999;4(3):155–164.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Stahlberg S, Manthey T, et al. Effect of extended-cycle regimen with an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on bleeding patterns, safety, acceptance and contraceptive efficacy. Contraception. 2011;84(2):133–143.
   PubMed Web of Science ®Google Scholar
• Ahrendt HJ, Makalová D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):436–444.
   PubMed Web of Science ®Google Scholar
• Mansour D, Westhoff C, Kher U, et al. Pooled analysis of two randomized, open-label studies comparing the effects of nomegestrol acetate/17β-estradiol and drospirenone/ethinyl estradiol on bleeding patterns in healthy women. Contraception. 2017;95(4):390.
   PubMed Web of Science ®Google Scholar
• Korver T. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 μg/day or levonorgestrel 30 μg/day: collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. Eur J Contracept Reprod Health Care. 1998;3(4):169–178.
   PubMedGoogle Scholar